DelveInsight’s, “Nasopharyngeal Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the Nasopharyngeal Cancer pipeline drug profiles, including Nasopharyngeal Cancer clinical trials and nonclinical stage products. It also covers the Nasopharyngeal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Nasopharyngeal Cancer emerging drugs, the Nasopharyngeal Cancer pipeline analysis report provides a 360° view of the Nasopharyngeal Cancer pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Nasopharyngeal Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Nasopharyngeal Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Nasopharyngeal Cancer clinical trials studies, Nasopharyngeal Cancer NDA approvals (if any), and product development activities comprising the technology, Nasopharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Nasopharyngeal Cancer Pipeline Report

 

• Over 30+ Nasopharyngeal Cancer companies are evaluating 30+ Nasopharyngeal Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Nasopharyngeal Cancer market would significantly increase market revenue.

 

• The leading Nasopharyngeal Cancer Companies includes Novartis Pharmaceuticals, Innovent Biologics, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme Corp, Tessa Therapeutics, Akeso Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Atara biotherapeutics, Incyte Corporation, Bristol-Myers Squibb, Hoffman La Roche, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Bristol-Myers Squibb, Hoffman La Roche, Klus Pharma, and others.

 

• Promising Nasopharyngeal Cancer Pipeline Therapies includes Oxaliplatin, capecitabine [Xeloda], Capecitabine, Cisplatin, Tislelizumab, Gemcitabin, SHR-1701, Albumin Paclitaxel, Erlotinib, Zometa (zoledronic acid), AK105, Camrelizumab, Spartalizumab, and others.

 

• The Nasopharyngeal Cancer Companies and academics are working to assess challenges and seek opportunities that could influence R&D. Nasopharyngeal Cancer The Nasopharyngeal Cancer pipeline therapies under development are focused on novel approaches to treat/improve Nasopharyngeal Cancer.

 

To explore more information on the latest breakthroughs in the Nasopharyngeal Cancer Pipeline treatment landscape of the report, click here @ Nasopharyngeal Cancer Pipeline Outlook

 

Nasopharyngeal Cancer Overview

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. In early cases Nasopharyngeal cancer may not cause any symptoms. The possible symptoms may include: lump in neck, blood in saliva, frequent ear infections, sore throat, nasal congestion, hearing loss. Tests and procedures used to diagnose nasopharyngeal carcinoma include: physical exam, nasal endoscopy and biopsy. Treatment for nasopharyngeal carcinoma usually begins with radiation therapy or a combination of radiation and chemotherapy.

 

Nasopharyngeal Cancer Emerging Drugs Profile

 

• Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.

Sintilimab, a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. The clinical trials for sintilimab are being evaluated for the treatment of Nasopharyngeal Neoplasms in phase III stage of development.

 

• Tislelizumab: BioGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. It is being studied in phase III stage of development for the treatment of Recurrent or Metastatic Nasopharyngeal Cancer.

 

• Tabelecleucel: Atara Biotherapeutics Inc.

Tabelecleucel, tab‐cel® is an off-the-shelf, allogeneic T-cell immunotherapy in phase I/II studies for the treatment of nasopharyngeal carcinoma.

 

• PDR001: Novartis Pharmaceuticals

PDR001 (anti-PD-1) is an investigational immunotherapy being developed by Novartis to treat both solid tumors and lymphomas. PDR001 is a type of immunotherapy, it acts by activating the body’s own immune system to recognize and fight cancer cells. The drug is being studied in phase II stage of development for the treatment of Nasopharyngeal cancer.

 

For further information, refer to the detailed Nasopharyngeal Cancer Unmet Needs, Nasopharyngeal Cancer Market Drivers, and Nasopharyngeal Cancer Market Barriers, click here for Nasopharyngeal Cancer Ongoing Clinical Trial Analysis

 

Nasopharyngeal Cancer Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for NASOPHARYNGEAL CANCER. The companies which have their Nasopharyngeal Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.

 

Nasopharyngeal Cancer Pipeline Segmentation

 

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

• Oral
• Subcutaneous
• Intravenous
• Intramuscular

 

Molecule Type

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
• Product Type

 

Request a sample and discover the recent advances in Nasopharyngeal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Nasopharyngeal Cancer Treatment Landscape

 

Scope of the Nasopharyngeal Cancer Pipeline Report

 

• Coverage- Global

 

• Nasopharyngeal Cancer Companies- Novartis Pharmaceuticals, Innovent Biologics, BeiGene, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme Corp, Tessa Therapeutics, Akeso Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Atara biotherapeutics, Incyte Corporation, Bristol-Myers Squibb, Hoffman La Roche, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Bristol-Myers Squibb, Hoffman La Roche, Klus Pharma, and others.

 

• Nasopharyngeal Cancer Pipeline Therapies- Oxaliplatin, capecitabine [Xeloda], Capecitabine, Cisplatin, Tislelizumab, Gemcitabin, SHR-1701, Albumin Paclitaxel, Erlotinib, Zometa (zoledronic acid), AK105, Camrelizumab, Spartalizumab, and others.

 

• Nasopharyngeal Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Nasopharyngeal Cancer Market Drivers and Nasopharyngeal Cancer Market Barriers, click here @ Nasopharyngeal Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Nasopharyngeal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nasopharyngeal Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Nasopharyngeal Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. PDR001: Novartis Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. SHR-1701: Jiangsu Hengrui Medicine Co.
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Nasopharyngeal Cancer Key Companies
23. Nasopharyngeal Cancer Key Products
24. Nasopharyngeal Cancer – Unmet Needs
25. Nasopharyngeal Cancer – Market Drivers and Barriers
26. Nasopharyngeal Cancer – Future Perspectives and Conclusion
27. Nasopharyngeal Cancer Analyst Views
28. Nasopharyngeal Cancer Key Companies
29. Appendix

 

Got Queries? Find out the related information on Nasopharyngeal Cancer Mergers and acquisitions, Nasopharyngeal Cancer Licensing Activities @ Nasopharyngeal Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services